2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-155041
    Antihypertensive agent 2 3049677-56-4 98%
    Antihypertensive agent 2 (Compound 4g) is an antihypertensive agent. Antihypertensive agent 2 has effective antagonistic activities against angiotensin II receptor 1. Antihypertensive agent 2 reduces the blood pressure with equal or more potency compared to Losartan (HY-17512).
    Antihypertensive agent 2
  • HY-155042
    Antihypertensive agent 3 3049677-53-1 98%
    Antihypertensive agent 3 (compound 4a) is an antagonis of angiotensin II receptor 1. Antihypertensive agent 3 exhibits antihypertensive activity in a spontaneously hypertensive rats (SHRs) model.
    Antihypertensive agent 3
  • HY-155297
    Nebidrazine 55248-23-2 98%
    Nebidrazine is a centrally-acting hypotensive agent compared to clonidine, demonstrating weaker cardiovascular effects in rats. It induces dose-dependent hypotension and bradycardia when administered intracerebroventricularly (i.c.v.), with significantly lower sedative potential than clonidine in conscious rats. Yohimbine attenuates the cardiovascular effects of both Nebidrazine and clonidine, suggesting involvement of central alpha-autoreceptors sensitive to yohimbine. Unlike clonidine, Nebidrazine does not affect peripheral alpha-adrenoceptors in pithed rats, indicating a selective central mechanism. Chemical sympathectomy reduces Nebidrazine's cardiovascular effects more than clonidine's, and metiamide diminishes responses to both drugs, implicating central histamine receptors. These findings highlight Nebidrazine's distinct pharmacological profile and potential therapeutic application in managing hypertension through central alpha-autoreceptor stimulation.
    Nebidrazine
  • HY-155737
    ET receptor antagonist 1 98%
    ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC50=0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model.
    ET receptor antagonist 1
  • HY-155738
    ET receptor antagonist 2 98%
    ET receptor antagonist 2 (compound 16j) is an orally active ET receptor antagonist (IC50=0.22 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 2 attenuates monocrotaline (HY-N0750) induced PAH in rat model.
    ET receptor antagonist 2
  • HY-155739
    ET receptor antagonist 3 98%
    ET receptor antagonist 3 (compound 17d) is an orally active ET receptor antagonist (IC50=0.26 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 3 attenuates monocrotaline (HY-N0750) induced PAH in rat model.
    ET receptor antagonist 3
  • HY-155801
    CRX 527 216014-14-1 98%
    CRX 527 is a TLR4 agonist. CRX 527 activates the MyD88-dependent, TRIF-dependent, and TRAF6/NF-κB signaling pathways downstream of TLR4, mimics lipid A, and regulates antigen processing and presentation by dendritic cells. CRX 527 stimulates innate immune responses and enhances vaccine efficacy. CRX 527 maintains the structural integrity of hematopoietic tissues, spleen and intestine, alleviates radiation-induced damage, preserves intestinal homeostasis, and inhibits apoptosis, inflammatory responses, oxidative stress and DNA damage. CRX 527 can be used in the research of acute radiation syndrome, melanoma, HPV-related tumors and intracerebral hemorrhage.
    CRX 527
  • HY-156017
    5-HT6R antagonist 1 98%
    5-HT6R antagonist 1 (Comopund 8) is a 5-HT6R antagonist (Ki: 5 nM). 5-HT6R antagonist 1 inhibits platelet aggregation. 5-HT6R antagonist 1 has excellent metabolic stability. 5-HT6R antagonist 1 reverses MK-801 (HY-15084B)-induced memory impairments in rats. 5-HT6R antagonist 1 can be used for Alzheimer's disease (AD) research.
    5-HT6R antagonist 1
  • HY-156101
    Latanoprost amide 919281-21-3 98%
    Latanoprost amide is a derivative of the F-prostaglandin (FP) receptor agonist Latanoprost (HY-B0577).
    Latanoprost amide
  • HY-156192
    CGS 24565 136583-72-7
    CGS 24565, a derivative of the antibiotic Rifamycin (HY-B1907A), is an orally active hypolipidemic agent. CGS 24565 can reduce plasma cholesterol levels in both primate and nonprimate species.
    CGS 24565
  • HY-156536
    RXFP1 receptor agonist-1 2924619-64-5 98%
    RXFP1 receptor agonist-1 (Example 2 peak2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-1 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 300 nM.
    RXFP1 receptor agonist-1
  • HY-156537
    RXFP1 receptor agonist-2 2924460-54-6 98%
    RXFP1 receptor agonist-2 (Example 124) is a RXFP1 receptor agonist. RXFP1 receptor agonist-2 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 1 nM.
    RXFP1 receptor agonist-2
  • HY-156539
    RXFP1 receptor agonist-4 2941376-76-5 98%
    RXFP1 receptor agonist-4 (Example 268) is a RXFP1 receptor agonist. RXFP1 receptor agonist-4 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 4.9 nM.
    RXFP1 receptor agonist-4
  • HY-156541
    RXFP1 receptor agonist-6 2941346-85-4 98%
    RXFP1 receptor agonist-6 (Example 7) is a RXFP1 receptor agonist. RXFP1 receptor agonist-6 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 12 nM.
    RXFP1 receptor agonist-6
  • HY-156542
    RXFP1 receptor agonist-7 2941484-13-3 98%
    RXFP1 receptor agonist-7 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-7 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 4.2 nM.
    RXFP1 receptor agonist-7
  • HY-156543
    RXFP1 receptor agonist-8 2941271-76-5 98%
    RXFP1 receptor agonist-8 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-8 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC50 value of 1.8 nM.
    RXFP1 receptor agonist-8
  • HY-156635
    TIE-2/VEGFR-2 kinase-IN-3 433224-09-0 98%
    TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 6.9 nM and 3.5 nM, respectively. TIE-2/VEGFR-2 kinase-IN-3 can be used for the research of angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-3
  • HY-156637
    TIE-2/VEGFR-2 kinase-IN-4 433224-29-4 98%
    TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC50 values of 5.2 nM and 5.1 nM, respectively. TIE-2/VEGFR-2 kinase-IN-4 can be used for the research of angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-4
  • HY-156638
    TIE-2/VEGFR-2 kinase-IN-5 1014407-83-0 98%
    TIE-2/VEGFR-2 kinase-IN-5 is an anti-angiogenic agent. TIE-2/VEGFR-2 kinase-IN-5 also is a potent TIE-2 and VEGFR-2 tyrosine kinase inhibitor with pIC50 values of 7.78 nM and 8.11 nM, respectively. TIE-2/VEGFR-2 kinase-IN-5 can be used for the research of angiogenesis.
    TIE-2/VEGFR-2 kinase-IN-5
  • HY-156976
    Sulcardine 343935-60-4 98%
    Sulcardine is a multi-ion channel blocker that can reduce INa and ICa with IC50 values of 26.9 µM and 69.2 µM, respectively. Sulcardine is a potent hNav1.5 channel blocker with a mild inhibitory effect on hERG channels. Sulcardine has anti-arrhythmic effects.
    Sulcardine
Cat. No. Product Name / Synonyms Application Reactivity